Lexaria Bioscience receives two medical treatment patents

Lexaria Bioscience announces two important new patent awards. The Company has received a new granted patent in Lexaria’s patent family #21: Compositions and Methods for Treating Hypertension. This is the Company’s third granted US patent in this patent family. As Lexaria has repeatedly demonstrated, DehydraTECH-processed cannabidiol has evidenced an ability to lower blood pressure in both acute dosing in hypertension as well as over a 5-week study duration. This patent will expire in 2042 if not extended. The Company has also received a new granted patent in Lexaria’s patent family #24: Compositions and Methods for Treating Epilepsy. This is the Company’s third granted US patent in this patent family. This patent complements earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in rodents, and was also absorbed into the bloodstream more effectively than the commercially available cannabinoid-based anti-seizure medication, Epidiolex. This patent will expire in 2042 if not extended. With the issuance of these two new patents, Lexaria’s patent portfolio has now grown to 43 granted patents worldwide. Lexaria’s intellectual property remains a significant component in supporting future business objectives.